{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2014"],"condition":["Metastatic Colorectal Cancer","Colorectal carcinoma","Colorectal cancer","Colorectal Neoplasms"],"disease":["Colorectal Carcinoma","Metastatic Colorectal Cancer","Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2161964"],"location":["Austria","Belgium","Italy","United Kingdom","France","Germany","Estonia","Spain"],"study_start_month":["9"],"keyword":["MCRC","CRC","Immunotherapy","Maintenance treatment","MGN1703","Metastatic","Immune modulation"],"repository":["ECRIN MDR"],"study_status":["Not provided"],"additional_accession":[]},"is_claimable":false,"name":"Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment","description":"The purpose of this this trial is to prove the efficacy and safety of MGN1703 as a maintenance therapy after first-line chemotherapeutic treatment of metastatic colorectal cancer.","dates":{"creation":"2014-09-15"},"accession":"2161964","cross_references":{"ClinicalTrials___gov":["NCT02077868"],"EU Clinical Trials Register":["2014-000834-50"]}}